anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/JP93/01766 Sec. 371 Date Oct. 6, 1994 Sec. 102(e) Date Oct. 6, 1994 PCT Filed Dec. 3, 1993 PCT Pub. No. WO94/13702 PCT Pub. Date Jun. 23, 1994The present invention relates to hematopoietic inhibiting factor-containing compositions which inhibit colony formation of CFU-E, comprising a substance obtained in the fraction eluting at exclusion limit by gel filtration using a gel having maximum molecular weight fractionation of not less than 200,000 and not more than 1,500,000, of a dialysate of blood which is obtained with a dialysis membrane having albumin sieving coefficient of not less than 0.01, followed by concentration with a membrane having molecular weight fractionation of not more than 5,000, and hematopoietic inhibiting factor-containing compositions which inhibit colony formation of CFU-E can be obtained. It further relates to a process of treating blood in which AI component is so removed as to satisfy AI/AA>/=1/50, wherein AI is the height of the absorbancy value of the hematopoietic inhibiting factor-containing compositions and AA is the height of the maximum absorbancy value in a gel filtration pattern of solutes of the dialysate expressed in terms of the absorbancy at 280 nm, and to a dialysis membrane which satisfies AI/AA>/=1/50. It further relates to drug compositions and a therapeutic agent for erythrocytosis, containing such hematopoietic inhibiting factor as the active ingredient.
H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
More frequent INR monitoring should be performed when starting or stopping botanicals.

Few adequate, well-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and JANTOVEN exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation.

Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of JANTOVEN. Conversely, some botanicals may decrease the effects of JANTOVEN (e.g., co-enzyme Q10, St. John's wort, ginseng). Some botanicals and foods can interact with JANTOVEN through CYP450 interactions (e.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. John's wort). 

The amount of vitamin K in food may affect therapy with JANTOVEN. Advise patients taking JANTOVEN to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking JANTOVEN should avoid drastic changes in dietary habits, such as eating large amounts of green leafy vegetables.
The invention discloses peach liquid for invigorating stomach and helping digestion, and belongs to the technical field of healthy beverage. The peach liquid is mainly prepared from peach which serves as a main material, fructus amomi, dried orange peel, hawthorn, malt, etc. functioning as main drugs as well as a proper amount of accessories, food additive and drinking water according to proportions. The peach liquid disclosed by the invention has the functions of tonifying spleen and promoting appetite, removing qi stagnation and breaking retention, regulating middle warmer and helping digestion, and has excellent effects on preventing and treating such symptoms as inappetence, dyspepsia, impairment by overeating and anorexia; the peach liquid, after being drunk, can promote appetite, eliminate polydipsia and remove stagnation. The peach liquid can be used for developing various varieties such as sugar and sugar-free products, to meet the demands of different consumer groups. The peach liquid disclosed by the invention is convenient to drink, good in taste and free from toxic and side effect, and has a broad market prospect.
Beta crystalline form of perindopril arginine salt (I), characterized by the X-ray diffraction diagram on powder, measured by a diffractometer (copper anticathode) and exhibited a Bragg angle 2 theta (expressed in percentage in relation to the most intense line), an interreticular distance (d), an intensity and a relative intensity, as given in table of the specification, is new. Beta crystalline form of perindopril arginine salt of formula (I), characterized by the X-ray diffraction diagram on powder, measured by a diffractometer (copper anticathode) and exhibited a Bragg angle 2 theta (expressed in percentage in relation to the most intense line), an interreticular distance (d), an intensity and a relative intensity, as given in table of the specification, is new. Independent claims are included for: (1) a composition comprising (I) in combination with inert and nontoxic vehicles; and (2) the preparation of (I). ACTIVITY : Cardiovascular-Gen; Hypotensive; Cardiant. MECHANISM OF ACTION : Angiotensin I converting enzyme inhibitor. No biological data given.
Patients should be advised to follow these step-by-step instructions for application of salicyclic acid with oak bark ointment: Hands should be washed thoroughly.

When using tubes, the tip of the tube should not come into contact with the area to be treated; the tube should be recapped tightly after each application.

If applying with a cotton-tipped applicator, which is recommended, use once and discard. Salicyclic acid with oak bark ointment should be applied twice a day for best results.

Gently rinse the area to be treated with saline or water and then pat dry. Salicyclic acid with oak bark ointment can be applied directly to the wound or placed on dry gauze and then placed on the wound. Wet-Packs or Wet-To-Dry Dressings are not recommended since they will dilute the ointment and decrease its effectiveness. Salicyclic acid with oak bark is designed to provide moisture to the wound.

Spread a generous quantity of salicyclic acid with oak bark ointment evenly over the desired area to yield a thin continuous layer of approximately 1/8 of an inch of thickness. There may be a mild warming sensation or slight burning, to the treated area for 3-5 minutes after application. If irritation occurs or symptoms persist after 10 days, discontinue use and consult your physician.

Try to keep the area being treated clean and exposed to air when possible. Apply an ap- propriate dressing to shield the area from clothes or exposure to water or dirt.

If there is no improvement in the wound within 7 days, consult your physician for further evaluation of the wound. If there is no response to the ointment at all, then the wound should be re-evaluated for other contributing factors to the wound healing process.
NEW MATERIAL:The compound of formula I (R is cyano, carbamoyl or 5- tetrazolyl; n is 2-6; n is not 2 when R is cyano) or its pharmacologically allowable salt. EXAMPLE:4-(3,5-Di-tert-butyl-4-hydroxy)phenylthiobutyronitrile. USE:A drug. It has excellent inhibiting action against the intake of LDL into macrophage, etc., and is useful for the prevention or remedy of arteriosclerosis, gastric ulcer, allergy, rheumatism, myocardial infarction, cataract, hepatic disorder, cerebral cell disorder, diabetes, thyropathy or inflammatory diseases. PREPARATION:The compound of formula I wherein R is CN and n is 3-6 can be produced by reacting 2,6-di-tert-butyl-4-mercaptophenol of formula II with an alkylation agent such as halogenonitrile (e.g. bromoalkanonitrile) in ethanol solvent in the presence of a basic substance such as NaOH.
Dose levels will be defined according to the same tasquinimod doses as in the single agent (Arm A1) dose escalation. Enrollment in arm B1 will not begin until enrollment in arm A1 has been completed and an MTD/optimal schedule has been established for single agent tasquinimod. Initial subjects in arm B1 will be enrolled at the lower of dose level 1 or one dose level below the single agent MTD . If this initial dose level is determined to exceed the combination MTD, further subjects will be enrolled at one dose level lower. Enrollment is not planned in arm B1 at doses higher than the single agent MTD. There are 9-12 planned subjects if all dose levels are explored.
The most cost-effective data collection method is electroencephalography (EEG) to obtain meaningful information about the brain. Therefore, EEG signal processing is very important for neuroscience and machine learning (ML). The primary objective of this research is to detect neonatal seizures and explain these seizures using the new version of Directed Lobish. This research uses a publicly available neonatal EEG signal dataset to get comparative results. In order to classify these EEG signals, an explainable feature engineering (EFE) model has been proposed. In this EFE model, there are four essential phases and these phases: (i) automaton and transformer-based feature extraction, (ii) feature selection deploying cumulative weight-based neighborhood component analysis (CWNCA), (iii) the Directed Lobish (DLob) and Causal Connectome Theory (CCT)-based explainable result generation and (iv) classification deploying t algorithm-based support vector machine (tSVM). In the first phase, we have used a channel transformer to get channel numbers and these values have been divided into three levels and these levels are named (1) high, (2) medium and (3) low. By utilizing these levels, we have created an automaton and this automaton has three nodes (each node defines each level). In the feature extraction phase, transition tables of these nodes has been extracted. Therefore, the proposed feature extraction function is termed Triple Nodes Automaton-based Transition table Pattern (TATPat). The used EEG signal dataset contains 19 channels and there are 9 (= 32) connection in the defined automaton. Thus, the presented TATPat extracts 3249 (= 19 × 19 × 9) features from each EEG segment. To choose the most informative features of these 3249 features, a new feature selector which is CWNCA has been applied. By cooperating findings of this feature selector and the presented DLob, the explainable results have been obtained. The last phase is the classification phase and to get high classification performance from this phase, an ensemble classifier (tSVM) has been presented and the classification results have been obtained using two validation techniques which are 10-fold cross-validation (CV) and leave-one subject-out (LOSO) CV. The proposed EFE model generates a DLob string and by using this string, the explainable results have been obtained. Moreover, the presented EFE model attained 99.15% and 76.37% classification accuracy deploying 10-fold and LOSO CVs respectively. According to the classification performances, the recommended TATPat-based EFE is a good model at EEG signal classification. Also, the presented TATPat-based EFE model is a good model for explainable artificial intelligence (XAI) since TTPat-based EFE is cooperating by the DLob.
Each presenting Patient with acute distal vessel occlusion of anterior circulation with (A1-A3)or (M2-M3) either mechanical thrombectomy (MT) with or without intra-venous thrombolysis (IVT) according to standard medical guidelines. MT was performed using approved aspiration catheters or stent-retrievers or both.
Recent artificial intelligence (AI) advancements in cardiovascular medicine offer potential enhancements in diagnosis, prediction, treatment, and outcomes. This article aims to provide a basic understanding of AI enabled ECG technology. Specific conditions and findings will be discussed, followed by reviewing associated terminology and methodology. In the appendix, definitions of AUC versus accuracy are explained. The application of deep learning models enables detecting diseases from normal electrocardiograms at accuracy not previously achieved by technology or human experts. Results with AI enabled ECG are encouraging as they considerably exceeded current screening models for specific conditions (i.e., atrial fibrillation, left ventricular dysfunction, aortic stenosis, and hypertrophic cardiomyopathy). This could potentially lead to a revitalization of the utilization of the ECG in the insurance domain. While we are embracing the findings with this rapidly evolving technology, but cautious optimism is still necessary at this point.
There is biologic plausibility for opioids in the treatment of dyspnea in PAH. Opioids have widespread effects including venodilation, vasodilation, reducing sympathetic outflow, blunting hypercapnic and hypoxic ventilatory responses, and altering the central perception of dyspnea. Although the origins of dyspnea in PAH are incompletely understood and multifactorial, right ventricular dysfunction reduces exercise capacity and likely also plays a role in the development of dyspnea. Mechanoreceptors situated in the right atrium and right ventricle sense elevated pressures and via sympathetic afferents may lead to an augmentation of ventilatory response and hence dyspnea. Morphine may specifically antagonize this feedback loop by causing venodilation and blunting sympathetics. Morphine also reduces central chemosensitivity and perceptions of dyspnea. Therefore, the drug may antagonize both peripheral and central drivers of dyspnea in PAH.

Investigators will conduct a single-center feasibility study of morphine for treatment of dyspnea and exercise intolerance in PAH. Participants will complete two 6-minute walk tests (6MWT) within one week. Participants will be randomly assigned to receive morphine prior to either the first or second 6MWT. Symptoms and 6-minute walk distance (6MWD) will be compared between the two tests.
PROBLEM TO BE SOLVED: To provide a method for preparing at least one kind of compound with biological properties from blood.SOLUTION: A method of the present invention is implemented in a closed tube under low atmospheric pressure (pressure lower than the atmospheric pressure) so that bacterial contamination of a compound through the handling is reduced or prevented. The method includes the repetition of the following steps for the desired number of times. A vacuum sealed second vacuum vessel is connected to a blood collection device connected to a first vessel containing blood separated into fractions. Waiting until a desired fraction is transferred, and the second vessel is pulled out. A variety of second vessels can be acquired that contain different compounds for different medical applications such as biological treatment. The steps of the invention can be performed in a closed system without opening the vessel. The first vessel may be opened before introducing the blood collection device.
Skin problems are common in returning travellers, despite the fact that vaccination, insect repellent techniques, adequate clothing and footwear are all ways to prevent skin disease. When travelling to unusual areas, the traveller can still expect to pick up diseases that are common across the world, such as lice, scabies, and staphylococcal or streptococcal infections. What can differ are the different arthropods and the diseases they can spread. Given the plethora of dermatoses in returning travellers, a methodological approach is necessary. We attempted such an approach by creating a practical guide that includes a diagnostic flowchart alongside a world map presenting common skin problems by continent. Additional information regarding possible investigations, along with tables presenting common infectious skin diseases and their corresponding presentations, is also included in our study. Our aim is to help clinicians approach skin dermatosis in patients returning from holidays, acknowledging the diagnostic difficulties that this might entail.
Primary non-response to the currently available direct acting anti-viral (DAAs) in chronic hepatitis C virus (HCV) is rare and expected in approximately only 3-4% of the patients. Among the plausible explanations, HCV resistant variant may be one of the causes among the several other viral and host factors implicated in cases who do not achieve cure. Ever since the approval of licensed DAAs in 2014, focus has been mainly on high cure rates. Hence, significantly less attention has been given to the few difficult to treat cases. We present, herein, the case of a 50-year old male who had previously failed to respond to the currently available first and second-line DAA treatment and was then approved for a special treatment access programme. According to our knowledge this is the first case-report from Pakistan in favour of the physician's directive for special treatment access for HCV DAA-experienced patients.
The invention discloses a composite liposome sensitive to high-intensity focused ultrasound (HIFU) and temperature, and applications thereof. The composite liposome is taken as a carrier used for drug intelligent controlled release under HIFU or heating. The composite liposome comprises at least one composite liposome forming lipid (CFL), at least one temperature-sensitive phospholipid, at least one lysophospholipid, and a lipid with covalently connected poly (ethylene glycol) (PEG). Temperature sensitive range of the composite liposome ranges from 39.0 to 45.0 DEG C; cyclicity is long; and the composite liposome is sensitive to HIFU. The invention also relates to applications of the HIFU and temperature sensitive composite liposome in controlled release of water soluble and amphiphilic anti-cancer drugs. The temperature sensitive composite liposome nanoparticle possesses excellent stability and biocompatibility, and excellent responsiveness capability on HIFU; under HIFU irradiation, the water soluble and amphiphilic anti-cancer drugs can be released out from the temperature sensitive composite liposome quickly; and curative effect is improved substantially.
The control group, on the other hand will include patients who either opt not to do the exercises or are on the waiting list for physiotherapy treatment. However, after completing the 12 weeks of no intervention, they will be asked whether they would like to receive physiotherapy treatment.
The invention provides calcium bucladesine sterile powder and a preparation thereof. The calcium bucladesine sterile powder is characterized in that the calcium bucladesine sterile powder is in an amorphous form state and has the purity of over 98 percent. Furthermore, the invention also provides amorphous calcium bucladesine sterile powder and a preparation method of a calcium bucladesine sterile powder preparation. The preparation method comprises the following steps: purifying chemically synthetic a crude calcium bucladesine solution through preparative high pressure liquid chromatography, concentrating, filtering, and performing freeze drying, thereby obtaining the sterile powder, wherein the X-ray powder diffraction and infrared absorption spectrum prove that the sterile powder refers to the amorphous calcium bucladesine sterile powder. Compared with a commercially available mixed crystal form calcium bucladesine powder-injection preparation, the amorphous calcium bucladesine sterile powder is high in content and high in stability. The amorphous calcium bucladesine sterile powder and the preparation thereof provided by the invention are used for treating angor pectoris, myocardial infarction, myocarditis, cardiogenic shock, immune genetic diseases such as lupus erythematosus and parapsoriasis guttata as well as other cardiovascular diseases.
The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
Sustained-release tablets are prepared by dissolving a medicament in a solvent to form a solution, mixing the solution with a water-insoluble lattice-forming material which is insoluble in the solvent, removing said solvent to obtain a substantially dry mixture and compressing said mixture into tablets which thereby have the medicament uniformly dispersed in the lattice structure formed by the water-insoluble material.  The lattice-forming material may be aluminium oxide, a water-insoluble metal salt of a fatty acid containing from 6-22 C. atoms e.g. calcium stearate, bentonite, silica gel, barium sulphate, or mixtures thereof.  The solvent may be water, a C1-6 alcohol or a mixture thereof.  Water-soluble forms of a wide range of drugs may be used e.g. antibiotics, steroids and vitamins. Optional ingredients are (a) inert, water-soluble carriers e.g. urea, glycine, glycol, polyvinyl pyrrolidone, polyvinyl alcohol or mixtures thereof; (b) water-resistant agents e.g. methyl cellulose, fatty acids, fatty alcohols, fatty esters, fatty oils and wax, which slow down the release of the drug; (c) surface-active agents e.g. sodium lauryl sulphate, polysorbates and bis-2-ethylhexyl sodium sulpho-succinate; (d) anti-acid or intestinal fluid solubilising agents e.g. cellulose acetate phthalate, starch acetate phthalate, polyvinyl acetate phthalate or mixtures thereof.  The optional ingredients and drug are put into solution and mixed uniformly with the water-insoluble particles.  Alternatively, the particles may be sprayed with the said solution of drug and modifiers.  In a modification, a non-reactive water-soluble carrier is dissolved in a solvent, the solution is mixed with the water-insoluble lattice-forming material, the solvent is removed, an enzyme is mixed with the dry mixture and the resultant product is compressed into tablets.
BACKGROUND: Vibrotactile stimulation has been studied in its efficacy of reducing freezing of gait (FOG) in patients with Parkinson's disease (PD). However, the results are still controversial. We evaluated the efficacy of a newly developed vibrotactile foot device on freezing severity and gait measures in PD patients with FOG.
OBJECTIVE: To evaluate the efficacy of vibrotactile foot device on PD patients with FOG.
METHODS: Thirty-three PD patients with FOG were examined during their "off" medication state. The efficacy of the vibrotactile foot device was evaluated using a gait protocol comprising walking trials with vibrotactile stimulation "off" and "on." Walking trials were videotaped for the offline rating by two movement disorder specialists. The Opal inertial sensor unit (128 Hz; Mobility Lab; APDM Inc., Portland, OR, USA) was used for quantitative gait analysis.
RESULTS: The results demonstrated 33.1% reduction in number of FOG episodes (P < 0.001) and 32.6% reduction of freezing episodes (P < 0.001). Quantitative gait analysis showed a significant increase in step length (P = 0.033). A moderate negative correlation was observed between the change of percent time frozen and age (r = -0.415, P = 0.016). 73% of participants reported minimal to substantial improvement in walking with this vibrating stimulation delivered by the vibrotactile foot device.
CONCLUSIONS: The vibrotactile foot device is an efficient device that could significantly reduce freezing severity and provide gait regulation to patients with PD experiencing frequent freezing. It could potentially be used in the home environment for improving the quality of life.